Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy

This study has suspended participant recruitment.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00935012
First received: July 6, 2009
Last updated: June 21, 2016
Last verified: June 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: December 2021
  Estimated Primary Completion Date: December 2021 (Final data collection date for primary outcome measure)